Anti-Mouse TIM-4 – Purified in vivo GOLD™ Functional Grade

Extracellular domains of TIM-4 (aa 1-288)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

RMT4-53 activity is directed against mouse TIM-4.

The T cell immunoglobulin and mucin domain containing protein (TIM) family encodes cell surface receptors that are involved in the regulation of T helper (Th) -1 and -2 cell-mediated immunity¹. TIM-4, which is preferentially expressed on macrophages and dendritic cells, is the natural ligand of TIM-1, and this binding leads to T-cell expansion and cytokine production. Unlike other members of the TIM family, TIM-4 lacks a putative tyrosine phosphorylation signal sequence in its intracellular domain. The TIM-4 gene maps to a locus associated with predisposition to asthma in both mice and humans and with its connection to TIM-1-triggered Th2 responsiveness, may be considered as a candidate disease/predisposition gene for asthma.

RMT4-53 was generated by linking the extracellular domains of TIM-4 (aa 1-288) to the Fc portion of mouse IgG2a². This protein product was then used to immunize Sprague Dawley rats. Subsequently, LN cells were fused with P3U1 myeloma cells. RMT4-53 reacts with TIM-4/NRK cells but not with parental NRK or other TIM family members.

TIM-4 blockade has been investigated for the treatment of cancer^3,4 and allograft rejection^2,5 using anti-TIM-4 clone RMT4-53. Additionally, RMT4-53 blockade of TIM-4 leads to increased induction of iTregs from naïve CD4⁺ T cells². Blockade with RMT4-53 has also been investigated in liver ischemia-reperfusion injury^6,7.

TIM-4 is expressed by antigen-presenting cells of the lymphoid lineage, preferentially by mature dendritic cells and macrophages.

Phosphatidylserine, TIM1

1 Meyers JH, Chakravarti S, Schlesinger D, et al. Nat Immunol. 6(5):455-464. 2005.
2 Yeung MY, McGrath MM, Nakayama M, et al. J Immunol. 191(8):4447-4455. 2013.
3 Baghdadi M, Nagao H, Yoshiyama H, et al. Cancer Immunol Immunother. 62(4):629-637.2013.
4 Ding Q, Mohib K, Kuchroo VK, et al. J Immunol. 199(7):2585-2595. 2017.
5 Vergani A, Gatti F, Lee KM, et al. Cell Transplant. 24(8):1599-1614. 2015.
6 Ji H, Liu Y, Zhang Y, et al. Hepatology. 60(6):2052-2064. 2014.
7 Li J, Zhao X, Liu X, et al. Mol Immunol. 66(2):117-125. 2015.